Pharmacy Times October 11, 2024
Key Takeaways
- EHR automation reduces biosimilar authorization turnaround from 12 to 4 days, aligning choices with insurance preferences.
- Mismatches between institutional and insurance-preferred biosimilars cause patient delays and step therapy requirements.
- Future EHR developments aim to expand automation to other pharmaceutical classes, enhancing efficiency and reducing duplicative steps.
In a Pharmacy Times® interview, Sarah Hudson-Disalle, PharmD, fellow of the Association of Cancer Care Centers (ACCC), and assistant director at James Cancer Hospital for Infusion Reimbursement Services, discussed the capabilities of EHR to automate biosimilar selection and access.
Pharmacy Times: What common barriers do patients experience regarding biosimilar selection and access?
Sarah Hudson-Disalle, PharmD: Biosimilars in the authorization process may be picked by the institution or the provider and...
Today's Sponsors
Today's Sponsor